v3.22.2.2
Nature of Business, Basis of Presentation and Significant Accounting Policies (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Aug. 05, 2021
USD ($)
Sep. 30, 2022
USD ($)
Jun. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Sep. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Sep. 30, 2022
USD ($)
distributor
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Net loss   $ (36,747) $ (49,942) $ (47,892) $ (17,670) $ (22,016) $ (18,909) $ (134,581) $ (58,595)  
Accumulated deficit   (389,991)           (389,991)   $ (255,410)
Cash and cash equivalents   68,800     184,166     68,800 184,166 193,372
Product revenue, net   5,591     $ 0     $ 12,988 $ 0  
Required recurring revenue for funding $ 40,000                  
Number of large wholesale drug distributors | distributor               4    
Cowen And Company, LLC                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Equity capital raised through at-the-market sales (up to)   $ 100,000           $ 100,000    
Revolving Credit Facility | OrbiMed Credit Facility                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
OrbiMed credit facility                   $ 125,000
Minimum liquidity covenant after FDA approval 5,000                  
Amount provided contingent upon certain net sales performance | Revolving Credit Facility | OrbiMed Credit Facility                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Contingent increase in credit facility $ 30,000